Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum]

Abstract

Giamberardino MA, Affaitati G, Costantini R, et al. J Pain Res. 2017;10:2751–2760.On page 2756, left column, lines 7 and 8: “Patients who previously had failed two preventative medications were excluded.” should have been: “Patients who previously had failed more than two preventive medications were excluded.”On page 2756, right column, lines 41–43: “There was a difference of −1.1 days in the main change in monthly migraine days between 70 mg erenumab group and placebo.” should have been: “There was a difference of −2.5 days in the mean change in monthly migraine  days between 70 mg erenumab group and placebo.”Read the original article